title: Ð¡ÑÐ°Ð²Ð½ÐµÐ½Ð¸Ðµ Ð¼ÐµÑÐ¾Ð´Ð¾Ð² Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð¸ Ð¼Ð°ÑÑ-ÑÐ¿ÐµÐºÑÑÐ¾Ð¼ÐµÑÑÐ¸Ð¸ Ð´Ð»Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð°Ð»ÑÑÐ°-1-Ð°Ð½ÑÐ¸ÑÑÐ¸Ð¿ÑÐ¸Ð½Ð° ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Comparison of methods of enzyme immunoassay and mass spectrometry for determining the concentration of human alpha-1-antitrypsin
Creators: name: Ð¢Ð¸ÑÐ¾Ð²Ð°, ÐÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: Ð¿ÑÐ¾ÑÐµÐ°Ð·Ñ
Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÑ ÑÐµÑÐ¸Ð½Ð¾Ð²ÑÑ Ð¿ÑÐ¾ÑÐµÐ°Ð·
Ð°Ð»ÑÑÐ°-1-Ð°Ð½ÑÐ¸ÑÑÐ¸Ð¿ÑÐ¸Ð½
ÑÑÐ¸Ð¿ÑÐ¸Ð½
Ð°Ð»ÑÑÐ°-2-Ð¼Ð°ÐºÑÐ¾Ð³Ð»Ð¾Ð±ÑÐ»Ð¸Ð½
Ð¼ÐµÑÐ¾Ð´ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° (ÐÐ¤Ð)
Ð¼ÐµÑÐ¾Ð´ Ð¼Ð°ÑÑ-ÑÐ¿ÐµÐºÑÑÐ¾Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° (ÐÐ¡)
proteases
serine protease inhibitors
alpha-1-antitrypsin
trypsin
alpha-2-macroglobulin
enzyme immunoassay (ELISA)
mass spectrometric analysis (MS)

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¾Ð¿Ð¸ÑÑÐ²Ð°ÐµÑ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ðµ Ð´Ð²ÑÑ Ð¼ÐµÑÐ¾Ð´Ð¾Ð² (Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° (ÐÐ¤Ð) Ð¸ Ð¼Ð°ÑÑ-ÑÐ¿ÐµÐºÑÑÐ¾Ð¼ÐµÑÑÐ¸Ð¸) Ð´Ð»Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð°Ð»ÑÑÐ°-1-Ð°Ð½ÑÐ¸ÑÑÐ¸Ð¿ÑÐ¸Ð½Ð° (Ð1ÐÐ¢) Ð² ÑÑÐ²Ð¾ÑÐ¾ÑÐºÐµ ÐºÑÐ¾Ð²Ð¸ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. Ð1ÐÐ¢ ÑÐ²Ð»ÑÐµÑÑÑ Ð±ÐµÐ»ÐºÐ¾Ð¼ Ð¾ÑÑÑÐ¾Ð¹ ÑÐ°Ð·Ñ (ÑÐ¾ ÐµÑÑÑ ÐµÐ³Ð¾ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ñ Ð²Ð¾Ð·ÑÐ°ÑÑÐ°ÐµÑ Ð¿ÑÐ¸ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸ÑÐµÐ»ÑÐ½ÑÑ Ð¿ÑÐ¾ÑÐµÑÑÐ°Ñ, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð¿ÑÐ¾ÑÐµÐºÐ°ÑÑ Ð² Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ðµ), Ð¿Ð¾ÑÑÐ¾Ð¼Ñ Ð±ÑÑÑÑÐ¾Ðµ Ð¸ ÑÐ¾ÑÐ½Ð¾Ðµ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÐµÐ³Ð¾ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐµÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°ÑÑ ÑÑÐ¸ Ð´Ð°Ð½Ð½ÑÐµ Ð´Ð»Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð¿ÑÐ¾ÑÐµÐºÐ°Ð½Ð¸Ñ ÑÐµÐ¿ÑÐ¸ÑÐ° Ñ Ð±Ð¾Ð»ÑÐ½Ð¾Ð³Ð¾, Ð° ÑÐ°ÐºÐ¶Ðµ Ð¿Ð¾Ð¼Ð¾Ð³Ð°ÐµÑ Ð² Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐµ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹ Ð»ÐµÐ³ÐºÐ¸Ñ. ÐÐ° Ð´Ð°Ð½Ð½ÑÐ¹ Ð¼Ð¾Ð¼ÐµÐ½Ñ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ñ Ð1ÐÐ¢ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÑÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¸Ð¼Ð¼ÑÐ½Ð¾ÑÐµÑÐ¼ÐµÐ½ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð°, Ð¾Ð´Ð½Ð°ÐºÐ¾ ÑÑÐ¾Ñ Ð¼ÐµÑÐ¾Ð´ Ð¸Ð¼ÐµÐµÑ ÑÑÐ´ Ð½ÐµÐ´Ð¾ÑÑÐ°ÑÐºÐ¾Ð² â Ð½Ð°Ð¸Ð±Ð¾Ð»ÐµÐµ Ð²Ð°Ð¶Ð½ÑÐ¼ Ð¸Ð· Ð½Ð¸Ñ ÑÐ²Ð»ÑÐµÑÑÑ ÑÐºÐ¾ÑÐ¾ÑÑÑ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° - ÑÐµÐ·ÑÐ»ÑÑÐ°Ñ Ð¼Ð¾Ð¶Ð½Ð¾ Ð¿Ð¾Ð»ÑÑÐ¸ÑÑ ÑÐ¾Ð»ÑÐºÐ¾ ÑÐ¿ÑÑÑÑ ÑÑÑÐºÐ¸. Ð¢Ð°Ðº ÐºÐ°Ðº Ð±ÑÑÑÑÐ¾Ðµ Ð¸ ÑÐ¾ÑÐ½Ð¾Ðµ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð1ÐÐ¢ Ð¸Ð³ÑÐ°ÐµÑ Ð±Ð¾Ð»ÑÑÑÑ ÑÐ¾Ð»Ñ Ð² ÑÐ¾Ð²ÑÐµÐ¼ÐµÐ½Ð½Ð¾Ð¹ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½Ðµ, Ð±ÑÐ»Ð¾ Ð¿ÑÐµÐ´Ð»Ð¾Ð¶ÐµÐ½Ð¾ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°ÑÑ Ð´Ð»Ñ ÑÑÐ¾Ð³Ð¾ Ð¼Ð°ÑÑ-ÑÐ¿ÐµÐºÑÑÐ¾Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð¼ÐµÑÐ¾Ð´, ÐºÐ¾ÑÐ¾ÑÑÐ¹ Ð¾ÑÐ½Ð¾Ð²Ð°Ð½ Ð½Ð° Ð²Ð·Ð°Ð¸Ð¼Ð¾Ð´ÐµÐ¹ÑÑÐ²Ð¸Ð¸ ÑÑÐ¸Ð¿ÑÐ¸Ð½Ð° Ñ ÐµÐ³Ð¾ Ð¾ÑÐ½Ð¾Ð²Ð½ÑÐ¼Ð¸ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÐ°Ð¼Ð¸ â Ð°Ð»ÑÑÐ°-1-Ð°Ð½ÑÐ¸ÑÑÐ¸Ð¿ÑÐ¸Ð½Ð¾Ð¼ Ð¸ Ð°Ð»ÑÑÐ°-2-Ð¼Ð°ÐºÑÐ¾Ð³Ð»Ð¾Ð±ÑÐ»Ð¸Ð½Ð¾Ð¼, Ð¾Ñ ÐºÐ¾ÑÐ¾ÑÐ¾Ð³Ð¾ Ð¿ÑÐ¸ Ð²Ð·Ð°Ð¸Ð¼Ð¾Ð´ÐµÐ¹ÑÑÐ²Ð¸Ð¸ Ñ ÑÑÐ¸Ð¿ÑÐ¸Ð½Ð¾Ð¼ Ð¾ÑÑÐµÐ¿Ð»ÑÐµÑÑÑ Ð¿ÐµÐ¿ÑÐ¸Ð´. ÐÐ°Ð½Ð½ÑÐ¹ Ð¼ÐµÑÐ¾Ð´ Ð±ÑÐ» Ð¾ÑÑÐ°Ð±Ð¾ÑÐ°Ð½ Ð½Ð° ÑÑÐ²Ð¾ÑÐ¾ÑÐºÐ°Ñ ÐºÑÐ¾Ð²Ð¸ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ñ, Ð±Ð¾Ð»ÑÐ½ÑÑ Ñ ÐÐ ÐÐ Ð¸ Ð±Ð¾Ð»ÑÐ½ÑÑ Ð² ÑÐµÐ¿ÑÐ¸ÑÐµÑÐºÐ¾Ð¼ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ð¸. ÐÐ¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ñ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ Ð1ÐÐ¢ Ð±ÑÐ»Ð¸ Ð·Ð½Ð°ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾ Ð²ÑÑÐµ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÑÐµÐ¿ÑÐ¸ÑÐ¾Ð¼. Ð ÐµÐ·ÑÐ»ÑÑÐ°ÑÑ, Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¼ÐµÑÐ¾Ð´Ð° Ð¼Ð°ÑÑ-ÑÐ¿ÐµÐºÑÑÐ¾Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð°, ÑÑÐ°Ð²Ð½Ð¸Ð²Ð°Ð»Ð¸ÑÑ Ñ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐ°Ð¼Ð¸ Ð¿Ð¾ÑÐ»Ðµ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ° Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÐÐ¤Ð, Ð¿ÑÐ¸ ÑÑÐ¾Ð¼ Ð´Ð»Ñ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² Ð²ÑÐµÑ ÑÑÐµÑ Ð³ÑÑÐ¿Ð¿ Ð½Ðµ Ð±ÑÐ»Ð¾ Ð½Ð°Ð¹Ð´ÐµÐ½Ð¾ ÑÑÑÐµÑÑÐ²ÐµÐ½Ð½ÑÑ Ð¾ÑÐ»Ð¸ÑÐ¸Ð¹, ÑÑÐ¾ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐµÑ ÑÐ´ÐµÐ»Ð°ÑÑ Ð²ÑÐ²Ð¾Ð´ Ð¾ ÑÐ¾Ð¼, ÑÑÐ¾ Ð¼Ð°ÑÑ-ÑÐ¿ÐµÐºÑÑÐ¾Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð¼ÐµÑÐ¾Ð´ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐµÑ ÑÐ¾ÑÐ½Ð¾ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÑÑÑ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ñ Ð°Ð»ÑÑÐ°-1-Ð°Ð½ÑÐ¸ÑÑÐ¸Ð¿ÑÐ¸Ð½Ð° Ð² ÑÑÐ²Ð¾ÑÐ¾ÑÐºÐµ ÐºÑÐ¾Ð²Ð¸ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°.
description: This work describes a comparison of two methods (enzyme immunoassay (ELISA) and mass spectrometry) for determining the concentration of alpha-1-antitrypsin (A1AT) in human serum. A1AT is an acute phase protein (that is, its concentration increases with various inflammatory processes that occur in the body), so a quick and accurate determination of its concentration allows you to use this data to analyze the course of sepsis in a patient, and also helps in the diagnosis of various lung diseases. At the moment, the concentration of human A1AT is determined using an enzyme immunoassay, but this method has a number of disadvantages â the result can be obtained only after a day. Since the rapid and accurate determination of the concentration of A1AT plays an important role in modern medicine, it was proposed to use a mass spectrometric method for this purpose, which is based on the interaction of trypsin with its main inhibitors â alpha-1-antitrypsin and alpha-2-macroglobulin, from which the peptide is cleaved off when interacting with trypsin. This method was tested on the blood sera of the control group, patients with ARVI and patients in a septic state. The obtained values of A1AT concentration were significantly higher in patients with sepsis. The results obtained by mass spectrometric analysis were compared with the results obtained after the experiment with ELISA, while no significant differences were found for the samples of all three groups, which allows us to conclude that the mass spectrometric method allows us to accurately determine the concentration of alpha-1-antitrypsin in human serum.